Investment Risk Analysis: PHARMA MACHINES LIMITED

1. Risk Rating: MEDIUM

Justification: While the company demonstrates a solid balance sheet with net assets of £316,792 and no long-term debt, there are concerning trends in profitability and cash depletion that warrant attention. The transition from profit accumulation to loss, combined with significant cash drawdown, suggests potential operational headwinds. However, the company's long operating history (incorporated 1975) and substantial working capital buffer mitigate immediate solvency concerns.

2. Key Concerns

Concern 1: Significant Cash Depletion

Cash at bank fell from £265,827 (2024) to £151,478 (2025), a reduction of £114,349 or approximately 43%. This is the most significant year-on-year cash decline in the available history. While the company still holds a reasonable cash balance, the rate of depletion raises questions about whether this reflects operational losses, capital investment, or extraordinary items. Without a filed profit & loss account, the drivers remain opaque.

Concern 2: Transition to Loss-Making

The profit and loss reserve declined from £315,724 to £311,792, indicating the company incurred a loss of approximately £3,932 during FY2025. This contrasts with the consistent profit accumulation seen in prior years (net assets grew from £53,949 in 2012 to £349,671 in 2022). While the loss is modest in absolute terms, it represents a deterioration in trading performance that requires monitoring.

Concern 3: Heavily Depreciated Tangible Assets

Tangible assets have a net book value of only £19,037 against a gross cost of £329,812, meaning assets are approximately 94% depreciated. Minimal capital expenditure (£358 additions in the year) suggests deferred asset replacement. Given the company operates in machinery repair (SIC 33120), aging equipment may impair operational capability and could require significant future capital outlay.

3. Positive Indicators

Strong Working Capital Position: Net current assets of £297,755 and a current ratio of approximately 5.7:1 (£361,455 / £63,700) provide substantial liquidity headroom. The company can comfortably meet short-term obligations.

Reduced Current Liabilities: Creditors fell from £157,267 to £63,700, a reduction of £93,567. This suggests the company actively reduced its trade payable obligations, possibly from the prior year's elevated position.

No Long-Term Debt: The balance sheet shows no creditors falling due after one year, indicating the company operates without leverage. This eliminates debt service risk and provides financial flexibility.

Long Operating History: Nearly 50 years of continuous operation since 1975 demonstrates business resilience and market staying power in the pharmaceutical machinery sector.

Regulatory Compliance: Accounts and confirmation statements are filed on time with no overdue items. No director disqualification records are noted.

4. Due Diligence Notes